drugset / Trial / NCT03168334

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

NCT03168334

Phase 3 Completed 801 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multi-center, randomized, double-blind, vehicle-controlled, 12-week study designed to assess the safety, efficacy, and tolerability of IDP-123 Lotion in comparison with IDP-123 Vehicle Lotion.

Timeline

Start
2017-07-11
Primary completion
2018-07-24
Completion
2018-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Tazarotene Small molecule 0.045 %

Indications